Hong Kong · Shenzhen · Hangzhou · Beijing

Precision Medicine
Molecular Diagnostics
Global Innovation

Connecting global innovation, empowering precision medicine.

Novobay Biotech — headquartered in Hong Kong with a global reach — is building a new ecosystem for precision medicine. We are dedicated to transforming cutting-edge biomedical innovation into tangible patient benefits, empowering healthcare professionals with high-quality solutions powered by advanced molecular diagnostics.

Discover Our Technology → Partner With Us →
About Us

Bridging Innovation and Clinical Practice

NovoBay Biotechnology Company Limited is a Hong Kong-based biotechnology company dedicated to bridging global biomedical innovation with clinical practice. Leveraging advanced molecular diagnostics as our entry point, we provide cutting-edge companion diagnostics solutions for multinational pharmaceutical companies, clinical research institutions, and drug trial centers — driving the global accessibility of precision medicine.

🌏

Global Reach

Headquartered in Hong Kong with operations across China

🔬

Dual-Platform

PCR POCT + Nanopore sequencing for comprehensive coverage

💊

CDx Focused

End-to-end companion diagnostics development support

Our Mission

Driving the Global Accessibility of Precision Medicine

Leveraging advanced molecular diagnostics as our entry point, we connect global biomedical innovation resources to provide cutting-edge companion diagnostics solutions for multinational pharmaceutical companies, clinical research institutions, and drug trial centers — driving the global accessibility of precision medicine.

Molecular Diagnostics
Companion Diagnostics
Global Accessibility
Our Technology

Dual-Platform Architecture

Redefining the Boundaries of Companion Diagnostics

PCR POCT Platform

Rapid, automated molecular testing at the point of care. Same-day results with minimal sample requirements.

  • 3–4 hour turnaround for same-day clinical decisions
  • Fully automated workflow — minimal operator intervention
  • No specialized laboratory required — deploy anywhere
  • Single FFPE section sufficient — ideal for scarce samples
Explore PCR POCT →

Nanopore Sequencing Platform

Long-read sequencing for comprehensive molecular profiling. Direct RNA sequencing, structural variation, and methylation detection in a single run.

  • Q20+ accuracy — reducing assembly errors
  • Direct RNA sequencing — no reverse transcription bias
  • Structural variation + methylation in one run
Explore Nanopore →
Explore Our Full Technology Portfolio →
CDx Development

Five Core Challenges in Companion Diagnostics

In the precision medicine era, companion diagnostics has become a core requirement for new drug approval.

1

Sample Scarcity & Quality

NGS failure rate 20–40% on FFPE samples; micro-lesion DNA often <1ng. Our PCR POCT platform requires only a single FFPE section.

2

Long Turnaround Time

Traditional NGS requires 2 weeks; multi-center trial wait times vary widely. Our PCR POCT delivers results in 3–4 hours.

3

Lack of Standardization

Different centers and platforms produce incomparable results; no unified reference standard. Our dual-platform enables unified quality management.

4

Limited Coverage

Single technology cannot cover the full spectrum from screening to deep profiling. Our dual-platform covers all scenarios from rapid screening to comprehensive molecular characterization.

5

Global Deployment Difficulty

Requires specialized labs and skilled personnel; weak infrastructure in developing regions. Our PCR POCT requires no specialized laboratory.

→

NOVOBAY dual-platform systematically addresses all five challenges

See How →
Our Solutions

End-to-End Companion Diagnostics Solutions

Companion Diagnostics Development

We partner with pharmaceutical companies to develop and validate companion diagnostics that accelerate drug development timelines and support regulatory submissions worldwide.

  • Biomarker assay development and validation
  • Multi-center clinical trial CDx deployment
  • Regulatory submission support (FDA, EMA, NMPA)
  • Quality management and standardization
Learn More →

Global Multi-Center Clinical Trial Support

Decentralized clinical trials demand diagnostics that work everywhere — not just in specialized laboratories. Our platforms are designed for global deployment.

  • Standardized workflow across multiple centers
  • On-site deployment in resource-limited areas
  • Rapid turnaround for enrollment decisions
  • Centralized data management and reporting
Learn More →
Leadership

Meet Our Leadership Team

James ZHU

James ZHU

Co-Founder

A healthcare executive with over 30 years of cross-regional leadership spanning North America and Greater China, holding senior leadership roles at several different global pharmaceutical companies. The expertise covers the full value chain: medical affairs, business operations, and marketing & sales. driving new product launches, lifecycle management, and patient access strategies across diverse regulatory environments. A former Board Member of the Hong Kong Association of Pharmaceutical Industry (HKAPI), played a pivotal role in shaping industry standards and fostering collaboration between multinational corporations and local stakeholders.

Qing LU

Qing LU

Co-Founder

Doctor of Law with years of international legal experience, majority of a decade in senior roles at a top securities house, and years of involvement in biotech entrepreneurship. Familiar with mainland China and Hong Kong capital markets as well as biopharmaceutical industry operations.

View Full Team Profiles →

Partner With Us

Building the Future of Precision Medicine Together

Whether you're a pharmaceutical company exploring CDx collaboration, a research institution seeking partnership, or simply want to learn more — we'd love to hear from you.

Explore Partnership Opportunities →
Get In Touch

Contact Us